agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
Key Financial Performance
Revenue $1.44 billion for Q3 2025, a slight decrease from $1.45 billion in Q3 2024. The year-over-year decline was due to lower-than-expected risk adjustment and the impact of market and payer contract exits.
Medical Margin Negative $57 million for Q3 2025, compared to negative $58 million in Q3 2024. The margin was impacted by elevated cost trends, lower-than-expected risk adjustment, and exited markets.
Adjusted EBITDA Negative $91 million for Q3 2025, compared to negative $96 million in Q3 2024. The improvement was due to lower geography entry costs and continued operating cost discipline.
Medicare Advantage Membership 503,000 members at the end of Q3 2025, down from 525,000 members in Q3 2024. The decline was attributed to a measured approach to membership growth and partner exits.
ACO REACH Membership 115,000 members in Q3 2025, down from 132,000 members in Q3 2024. The decline was due to partner exits and a smaller 2025 class.
Operating Cost Reduction $30 million reduction in operating costs achieved through centralization, technology implementation, and alignment with PCP partners.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Enhanced Data Pipeline: agilon has implemented an enhanced data pipeline that provides timely direct payer data feeds, validated member-level clinical and claims data, and member-level risk scores for approximately 80% of members.
Clinical Pathways: Developed in collaboration with physician partners and national experts, these pathways focus on high-prevalence chronic conditions like heart failure, reducing inpatient diagnosis rates and improving medication adherence.
Palliative Care Program: Focuses on providing care in hospice or home settings, improving care satisfaction and reducing hospital admissions.
COPD and Dementia Pilots: Expansion of these pilots is planned for 2026.
Payer Contracting: Negotiations with payer partners for 2026 include reducing Part D exposure, expanding quality incentives, and improving economic terms for Part C.
Membership Strategy: A disciplined approach to membership growth has resulted in a slight year-over-year decline in Medicare Advantage and ACO REACH membership.
Cost Reduction: Operating costs have been reduced by $30 million through centralization, technology implementation, and alignment with PCP partners.
Stars Ratings: Approximately 75% of agilon members are expected to be in 4+ Star plans in 2027, up from 71% in 2026.
Focus on Profitability: agilon is prioritizing profitable growth by taking a disciplined approach to payer contracting and focusing on markets with favorable economics.
Reverse Stock Split: The company anticipates pursuing a reverse stock split and will seek stockholder approval in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Lower-than-expected in-year RAF contribution: The company faced challenges due to lower-than-expected in-year RAF contribution, which negatively impacted financial performance.
High costs from exited markets: Continued high costs from exited markets have been a financial burden, affecting profitability.
Lower-than-expected risk scores for 2025: Risk scores for 2025 were lower than anticipated, leading to a $150 million negative impact on medical margin.
Membership decline: Medicare Advantage membership declined from 525,000 in Q3 2024 to 503,000 in Q3 2025, partly due to partner exits and a smaller 2025 class.
Elevated medical cost trends: Medical cost trends remain elevated, particularly in inpatient and Part D oncology drugs, impacting financial performance.
Challenges in payer contract negotiations: The company is facing challenges in negotiating favorable payer contracts, which may result in reduced membership if terms are not met.
Exposure to Part D and supplemental benefits: The company continues to face risks from Part D exposure and supplemental benefits, which have been detrimental to capitated economics.
Operational cost structure alignment: Efforts to optimize the cost structure have led to headcount reductions and streamlined operations, but these changes may pose risks to operational efficiency.
Limited claims visibility: The company has limited visibility into paid claims post-quarter close, which complicates accurate forecasting and financial planning.
Potential membership reduction due to contracting strategy: The disciplined approach to payer contracting may lead to reduced membership in 2026, impacting revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: Revenue is expected to be in the range of $5.81 billion to $5.83 billion, reflecting membership shifts, improved revenue yield from payer contracts, and lower-than-expected 2025 risk adjustment performance.
2025 Medical Margin Guidance: Full year medical margins are projected to be between negative $5 million to $15 million.
2025 Adjusted EBITDA Guidance: Adjusted EBITDA guidance range is negative $270 million to negative $245 million.
2026 Revenue and Margin Expectations: Revenue growth on a PMPM basis is expected to exceed the 9% CMS final rate notice for 2026, driven by better aligned payer contracts and enhanced quality incentives.
2026 Operating Expense Reduction: Operating expense initiatives are expected to reduce costs by approximately $30 million in 2026.
2026 Membership and Contracting Strategy: Membership may decline in 2026 due to a disciplined approach to payer contracting, focusing on profitability and favorable economics. Some members may transition to care coordination fee arrangements.
2026 Medical Margin and Adjusted EBITDA: Tailwinds such as macro factors, better payer contracts, and cost actions are expected to drive material improvement in medical margin and adjusted EBITDA in 2026.
2026 Cash Position: The company expects to end 2026 with at least $100 million in cash on the balance sheet, including cash held in ACO REACH entities.
2026 Quality and Stars Ratings: Approximately 75% of members are expected to be in 4+ Star plans in 2026, supporting improved payer economics and quality performance.
Clinical Pathways and BOI Program Impact: Programs like heart failure pathways and palliative care are expected to positively contribute to financial results in 2026, with expanded pilots for COPD and dementia.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the expected EBITDA impact of the ACO REACH program changes, and how is agilon addressing it?
A:The narrowing of the savings rate in the ACO REACH program is expected to have a negative economic impact, but the re-baselining of risk adjustment is more meaningful. Agilon is reviewing its ACOs and considering moving some to the MSSP program by 2026 for better economics. The exact impact is not sized yet.
Q:Are there plans for market exits or changes in payer contracts?
A:Agilon is taking a disciplined approach to payer contracts, focusing on profitability and medical margin improvement. Market exits are not ruled out, and some members may move to other payers or care management deals. The company is working with payers to align on objectives.
Q:What is the status of the CEO search?
A:The CEO search is ongoing with both internal and external candidates being considered. There is no timeline for a conclusion, but the Executive Chairman is actively engaged in improving business performance during the interim.
Q:What are the trends in medical costs for Q3 and expectations for Q4?
A:Medical cost trends in Q3 were consistent with prior quarters, with inpatient and Part B drug spend (especially oncology) running high. Q1 and Q2 trends have restated favorably, and Q3 estimates are conservative. The company will monitor Q4 trends as more data becomes available.
Q:What is the cash position at the ACO REACH entity level, and how is it managed?
A:At the end of the quarter, there was $172 million in the REACH entities, expected to settle to $65 million by year-end. The year-end cash balance of $310 million includes this $65 million. There is no requirement to hold cash in REACH entities, but it is tax-efficient to do so.
Q:Why is there a higher-than-average impact on risk revenue for certain members?
A:The higher impact is due to a new payer in 2024 for which data was unavailable in 2023, making risk score estimation challenging. Enhanced data pipelines now allow for better member-level risk score calculations, improving accuracy for future projections.
Q:What is CMS estimating for fee-for-service trends in 2025, and how do payer bids impact 2026?
A:CMS estimates fee-for-service cost trends at 8.5% for 2025. Payer bids are generally pricing for margin, which is expected to be a tailwind for agilon in 2026. Benefit designs vary by payer but are broadly positive across the network.
Q:What are the expected savings from the Palliative and Heart Failure Program, and how do clinical programs evolve?
A:Savings from these programs are not specified, but they are expected to reduce medical expenses and improve disease burden identification. Programs are piloted and rolled out market by market, with permanent implementation and continuous improvement planned.
Q:Are there changes to provider contracts, particularly regarding risk sharing?
A:There are no changes to provider contracts. Incentive alignment with physician partners was reviewed as part of $30 million in operating savings, but it was a small component of the total savings.
Q:What is the status of payer contracts for next year, and how does benefit misalignment affect them?
A:About 50% of contracts were open for renewal, with general agreements reached on a substantial portion. Benefit misalignment is analyzed market by market and addressed during contracting. Physician partners are actively involved in negotiations.
Q:How do Stars ratings and payer reductions impact agilon?
A:Stars ratings are a key component of contracting. Agilon seeks overall economics that make sense for its partners and itself, taking a disciplined approach to address potential volatility in Stars ratings.
Q:What is the timeline for rolling out clinical programs like COPD and dementia?
A:Programs are piloted for 6-8 months before broader rollout, starting with markets offering the most value. COPD and dementia programs will expand in 2026, with new pilots also being considered.
Q:What is the expected impact of the Big Beautiful Bill Act on agilon's business?
A:The act is not expected to have a meaningful impact on agilon's business.
Q:How does Humana's focus on benefit stability for 2026 affect agilon's medical costs?
A:Humana's benefit stability is part of the overall contracting process, where agilon analyzes plan designs and seeks favorable economics. The process is consistent across all payers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical details or direct answers to several questions, including the exact EBITDA impact of ACO REACH changes, the size of potential membership reductions, the timeline for the CEO search, specific PMPM savings from clinical programs, and the minimum working capital required. Additionally, responses about incentive alignment and Stars ratings lacked detailed explanations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Baird Co
Bank PLC
Barclays Bank
Care gap
Co Incorporated
Division Barclays
Division Needham
Division Truist
Inc Research
Incorporated Research
Investor Relations
LLC Research
Needham LLC
Research Division
Securities
Stars
agilon Health
average star
condition
contracting payer
deductible
diagnosis
economics
focus
heart failure
identification
pathway
patient heart
pharmacy solution
rate average
rating agilon
respect
screening
setting
AGL Transcript
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The company's earnings call presents a mix of positive and cautious elements. While there is optimism in revenue expectations and strategic initiatives, uncertainties in payer incentives and lack of clarity on AI risk adjustments temper enthusiasm. The market cap suggests moderate volatility, aligning with a neutral sentiment as the company navigates both growth opportunities and operational challenges.
agilon health, inc. (AGL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
agilon health, inc. (AGL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
AGL Slides
AGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
